SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19

Long-term antibody responses and neutralizing activities in response to SARS-CoV-2 infection are not yet clear. Here we quantify immunoglobulin M (IgM) and G (IgG) antibodies recognizing the SARS-CoV-2 receptor-binding domain (RBD) of the spike (S) or the nucleocapsid (N) protein, and neutralizing a...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Nature communications Ročník 12; číslo 1; s. 1813 - 9
Hlavní autoři:	Wu, Jun, Liang, Boyun, Chen, Cunrong, Wang, Hua, Fang, Yaohui, Shen, Shu, Yang, Xiaoli, Wang, Baoju, Chen, Liangkai, Chen, Qi, Wu, Yang, Liu, Jia, Yang, Xuecheng, Li, Wei, Zhu, Bin, Zhou, Wenqing, Wang, Huan, Li, Sumeng, Lu, Sihong, Liu, Di, Li, Huadong, Krawczyk, Adalbert, Lu, Mengji, Yang, Dongliang, Deng, Fei, Dittmer, Ulf, Trilling, Mirko, Zheng, Xin
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	London Nature Publishing Group UK 22.03.2021 Nature Publishing Group Nature Portfolio
Témata:	13/1 631/250/2152/2153/1291 631/326/596/4130 692/699/255/2514 Adult Aged Antibodies Antibodies, Neutralizing - immunology Antibodies, Viral - immunology Binding Contraction Coronaviruses COVID-19 COVID-19 - immunology Female Humanities and Social Sciences Humans Humoral immunity Immune response Immune response (humoral) Immunity Immunity, Humoral - immunology Immunoglobulin G Immunoglobulin G - immunology Immunoglobulin M Immunoglobulin M - immunology Male Middle Aged multidisciplinary Neutralizing Nucleocapsids SARS-CoV-2 - immunology Science Science (multidisciplinary) Severe acute respiratory syndrome coronavirus 2 Severity of Illness Index Spike Glycoprotein, Coronavirus Spikes Viral diseases
ISSN:	2041-1723, 2041-1723
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	Long-term antibody responses and neutralizing activities in response to SARS-CoV-2 infection are not yet clear. Here we quantify immunoglobulin M (IgM) and G (IgG) antibodies recognizing the SARS-CoV-2 receptor-binding domain (RBD) of the spike (S) or the nucleocapsid (N) protein, and neutralizing antibodies during a period of 6 months from COVID-19 disease onset in 349 symptomatic COVID-19 patients who were among the first be infected world-wide. The positivity rate and magnitude of IgM-S and IgG-N responses increase rapidly. High levels of IgM-S/N and IgG-S/N at 2-3 weeks after disease onset are associated with virus control and IgG-S titers correlate closely with the capacity to neutralize SARS-CoV-2. Although specific IgM-S/N become undetectable 12 weeks after disease onset in most patients, IgG-S/N titers have an intermediate contraction phase, but stabilize at relatively high levels over the 6 month observation period. At late time points, the positivity rates for binding and neutralizing SARS-CoV-2-specific antibodies are still >70%. These data indicate sustained humoral immunity in recovered patients who had symptomatic COVID-19, suggesting prolonged immunity. A better understanding of longitudinal changes in antibody responses in COVID-19 patients is needed. Here the authors analyze anti-spike and anti-nucleocapsid antibody responses to Sars-CoV-2 over a course of 6 months in a large cohort of patients with COVID-19, showing that IgM is mostly not detectable after 3 months, whereas IgG responses contract, yet remain at high levels at 6 months.
AbstractList	Long-term antibody responses and neutralizing activities in response to SARS-CoV-2 infection are not yet clear. Here we quantify immunoglobulin M (IgM) and G (IgG) antibodies recognizing the SARS-CoV-2 receptor-binding domain (RBD) of the spike (S) or the nucleocapsid (N) protein, and neutralizing antibodies during a period of 6 months from COVID-19 disease onset in 349 symptomatic COVID-19 patients who were among the first be infected world-wide. The positivity rate and magnitude of IgM-S and IgG-N responses increase rapidly. High levels of IgM-S/N and IgG-S/N at 2-3 weeks after disease onset are associated with virus control and IgG-S titers correlate closely with the capacity to neutralize SARS-CoV-2. Although specific IgM-S/N become undetectable 12 weeks after disease onset in most patients, IgG-S/N titers have an intermediate contraction phase, but stabilize at relatively high levels over the 6 month observation period. At late time points, the positivity rates for binding and neutralizing SARS-CoV-2-specific antibodies are still >70%. These data indicate sustained humoral immunity in recovered patients who had symptomatic COVID-19, suggesting prolonged immunity. A better understanding of longitudinal changes in antibody responses in COVID-19 patients is needed. Here the authors analyze anti-spike and anti-nucleocapsid antibody responses to Sars-CoV-2 over a course of 6 months in a large cohort of patients with COVID-19, showing that IgM is mostly not detectable after 3 months, whereas IgG responses contract, yet remain at high levels at 6 months. Long-term antibody responses and neutralizing activities in response to SARS-CoV-2 infection are not yet clear. Here we quantify immunoglobulin M (IgM) and G (IgG) antibodies recognizing the SARS-CoV-2 receptor-binding domain (RBD) of the spike (S) or the nucleocapsid (N) protein, and neutralizing antibodies during a period of 6 months from COVID-19 disease onset in 349 symptomatic COVID-19 patients who were among the first be infected world-wide. The positivity rate and magnitude of IgM-S and IgG-N responses increase rapidly. High levels of IgM-S/N and IgG-S/N at 2-3 weeks after disease onset are associated with virus control and IgG-S titers correlate closely with the capacity to neutralize SARS-CoV-2. Although specific IgM-S/N become undetectable 12 weeks after disease onset in most patients, IgG-S/N titers have an intermediate contraction phase, but stabilize at relatively high levels over the 6 month observation period. At late time points, the positivity rates for binding and neutralizing SARS-CoV-2-specific antibodies are still >70%. These data indicate sustained humoral immunity in recovered patients who had symptomatic COVID-19, suggesting prolonged immunity. Long-term antibody responses and neutralizing activities in response to SARS-CoV-2 infection are not yet clear. Here we quantify immunoglobulin M (IgM) and G (IgG) antibodies recognizing the SARS-CoV-2 receptor-binding domain (RBD) of the spike (S) or the nucleocapsid (N) protein, and neutralizing antibodies during a period of 6 months from COVID-19 disease onset in 349 symptomatic COVID-19 patients who were among the first be infected world-wide. The positivity rate and magnitude of IgM-S and IgG-N responses increase rapidly. High levels of IgM-S/N and IgG-S/N at 2-3 weeks after disease onset are associated with virus control and IgG-S titers correlate closely with the capacity to neutralize SARS-CoV-2. Although specific IgM-S/N become undetectable 12 weeks after disease onset in most patients, IgG-S/N titers have an intermediate contraction phase, but stabilize at relatively high levels over the 6 month observation period. At late time points, the positivity rates for binding and neutralizing SARS-CoV-2-specific antibodies are still >70%. These data indicate sustained humoral immunity in recovered patients who had symptomatic COVID-19, suggesting prolonged immunity. A better understanding of longitudinal changes in antibody responses in COVID-19 patients is needed. Here the authors analyze anti-spike and anti-nucleocapsid antibody responses to Sars-CoV-2 over a course of 6 months in a large cohort of patients with COVID-19, showing that IgM is mostly not detectable after 3 months, whereas IgG responses contract, yet remain at high levels at 6 months. A better understanding of longitudinal changes in antibody responses in COVID-19 patients is needed. Here the authors analyze anti-spike and anti-nucleocapsid antibody responses to Sars-CoV-2 over a course of 6 months in a large cohort of patients with COVID-19, showing that IgM is mostly not detectable after 3 months, whereas IgG responses contract, yet remain at high levels at 6 months. Long-term antibody responses and neutralizing activities in response to SARS-CoV-2 infection are not yet clear. Here we quantify immunoglobulin M (IgM) and G (IgG) antibodies recognizing the SARS-CoV-2 receptor-binding domain (RBD) of the spike (S) or the nucleocapsid (N) protein, and neutralizing antibodies during a period of 6 months from COVID-19 disease onset in 349 symptomatic COVID-19 patients who were among the first be infected world-wide. The positivity rate and magnitude of IgM-S and IgG-N responses increase rapidly. High levels of IgM-S/N and IgG-S/N at 2-3 weeks after disease onset are associated with virus control and IgG-S titers correlate closely with the capacity to neutralize SARS-CoV-2. Although specific IgM-S/N become undetectable 12 weeks after disease onset in most patients, IgG-S/N titers have an intermediate contraction phase, but stabilize at relatively high levels over the 6 month observation period. At late time points, the positivity rates for binding and neutralizing SARS-CoV-2-specific antibodies are still >70%. These data indicate sustained humoral immunity in recovered patients who had symptomatic COVID-19, suggesting prolonged immunity.Long-term antibody responses and neutralizing activities in response to SARS-CoV-2 infection are not yet clear. Here we quantify immunoglobulin M (IgM) and G (IgG) antibodies recognizing the SARS-CoV-2 receptor-binding domain (RBD) of the spike (S) or the nucleocapsid (N) protein, and neutralizing antibodies during a period of 6 months from COVID-19 disease onset in 349 symptomatic COVID-19 patients who were among the first be infected world-wide. The positivity rate and magnitude of IgM-S and IgG-N responses increase rapidly. High levels of IgM-S/N and IgG-S/N at 2-3 weeks after disease onset are associated with virus control and IgG-S titers correlate closely with the capacity to neutralize SARS-CoV-2. Although specific IgM-S/N become undetectable 12 weeks after disease onset in most patients, IgG-S/N titers have an intermediate contraction phase, but stabilize at relatively high levels over the 6 month observation period. At late time points, the positivity rates for binding and neutralizing SARS-CoV-2-specific antibodies are still >70%. These data indicate sustained humoral immunity in recovered patients who had symptomatic COVID-19, suggesting prolonged immunity.
ArticleNumber	1813
Author	Li, Sumeng Li, Wei Yang, Xiaoli Wang, Baoju Zhou, Wenqing Wu, Jun Wu, Yang Liu, Di Zheng, Xin Liu, Jia Yang, Dongliang Wang, Hua Yang, Xuecheng Chen, Cunrong Chen, Liangkai Dittmer, Ulf Trilling, Mirko Chen, Qi Fang, Yaohui Deng, Fei Wang, Huan Krawczyk, Adalbert Liang, Boyun Zhu, Bin Lu, Sihong Lu, Mengji Li, Huadong Shen, Shu
Author_xml	– sequence: 1 givenname: Jun orcidid: 0000-0002-8312-9832 surname: Wu fullname: Wu, Jun organization: Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology – sequence: 2 givenname: Boyun surname: Liang fullname: Liang, Boyun organization: Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology – sequence: 3 givenname: Cunrong surname: Chen fullname: Chen, Cunrong organization: Department of ICU, Fujian Medical University Union Hospital – sequence: 4 givenname: Hua surname: Wang fullname: Wang, Hua organization: Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology – sequence: 5 givenname: Yaohui surname: Fang fullname: Fang, Yaohui organization: State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences – sequence: 6 givenname: Shu orcidid: 0000-0002-0013-5365 surname: Shen fullname: Shen, Shu organization: State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences – sequence: 7 givenname: Xiaoli surname: Yang fullname: Yang, Xiaoli organization: Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology – sequence: 8 givenname: Baoju surname: Wang fullname: Wang, Baoju organization: Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology – sequence: 9 givenname: Liangkai orcidid: 0000-0002-5227-4236 surname: Chen fullname: Chen, Liangkai organization: Department of Nutrition and Food Hygiene, Hubei Key Laboratory of Food Nutrition and Safety, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Ministry of Education Key Lab of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology – sequence: 10 givenname: Qi surname: Chen fullname: Chen, Qi organization: Hubei Provincial Center for Disease Control and Prevention – sequence: 11 givenname: Yang surname: Wu fullname: Wu, Yang organization: Hubei Provincial Center for Disease Control and Prevention – sequence: 12 givenname: Jia surname: Liu fullname: Liu, Jia organization: Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology – sequence: 13 givenname: Xuecheng surname: Yang fullname: Yang, Xuecheng organization: Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology – sequence: 14 givenname: Wei surname: Li fullname: Li, Wei organization: Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology – sequence: 15 givenname: Bin surname: Zhu fullname: Zhu, Bin organization: Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology – sequence: 16 givenname: Wenqing surname: Zhou fullname: Zhou, Wenqing organization: Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology – sequence: 17 givenname: Huan surname: Wang fullname: Wang, Huan organization: Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology – sequence: 18 givenname: Sumeng surname: Li fullname: Li, Sumeng organization: Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology – sequence: 19 givenname: Sihong surname: Lu fullname: Lu, Sihong organization: Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology – sequence: 20 givenname: Di surname: Liu fullname: Liu, Di organization: Pritzker School of Medicine, University of Chicago – sequence: 21 givenname: Huadong surname: Li fullname: Li, Huadong organization: Jin Yin-tan Hospital – sequence: 22 givenname: Adalbert orcidid: 0000-0001-9502-9903 surname: Krawczyk fullname: Krawczyk, Adalbert organization: Department of Infectious Diseases, University Hospital of Essen, University of Duisburg-Essen – sequence: 23 givenname: Mengji surname: Lu fullname: Lu, Mengji organization: Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Institute for Virology, University Hospital of Essen, University of Duisburg-Essen – sequence: 24 givenname: Dongliang surname: Yang fullname: Yang, Dongliang organization: Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology – sequence: 25 givenname: Fei orcidid: 0000-0002-5385-083X surname: Deng fullname: Deng, Fei email: df@wh.iov.cn organization: State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences – sequence: 26 givenname: Ulf surname: Dittmer fullname: Dittmer, Ulf email: ulf.dittmer@uni-due.de organization: Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Institute for Virology, University Hospital of Essen, University of Duisburg-Essen – sequence: 27 givenname: Mirko orcidid: 0000-0003-3659-3541 surname: Trilling fullname: Trilling, Mirko email: mirko.trilling@uni-due.de organization: Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Institute for Virology, University Hospital of Essen, University of Duisburg-Essen – sequence: 28 givenname: Xin surname: Zheng fullname: Zheng, Xin email: xin11@hotmail.com organization: Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/33753738$$D View this record in MEDLINE/PubMed
BookMark	eNp9Uk1v1DAUjFAR_aB_gAOyxIWLwZ-xc0GqFgorVapEoVfLceytV4m92Emr_nucpoW2h_ryLL95o_G8Oaz2Qgy2qt5h9AkjKj9nhlktICIYEoIog_hVdUAQwxALQvce3fer45y3qBzaYMnYm2qfUsGpoPKgurk4-XkBV_ESEuCDs2b0MZRbNxmbQZ7yqH2wHbiahph0D_wwTMGCZPMuhlwgPgATw7XubTY2jGCnR19qBi72fbzxYQPy7bAb41AaBqzOL9dfIW7eVq-d7rM9vq9H1e_Tb79WP-DZ-ff16uQMGs7QCClzRXJjBKopdgxpgjDXxGHsuppIY6XRyCHN2q6pSW2x4Lqmtm5IW7dUYHpUrRfeLuqt2iU_6HSrovbq7iGmjdKpCOutkqLllrakqzlnhHeaGeIc464VUrIOFa4vC9duagfbzd8tljwhfdoJ_kpt4rUSjSx2zwQf7wlS_DPZPKrBF9f6Xgcbp6wIR4wy2TS8QD88g27jlEKxakZRTjhrREG9f6zon5SH_RaAXAAmxZyTdcr4Uc87LgJ9rzBSc5rUkiZV0qTu0qRm58iz0Qf2F4foMpQLOGxs-i_7ham_yC7cCQ
CitedBy_id	crossref_primary_10_1371_journal_pntd_0010102 crossref_primary_10_3390_vaccines10111948 crossref_primary_10_7554_eLife_77943 crossref_primary_10_3390_app122412971 crossref_primary_10_1093_abt_tbab013 crossref_primary_10_2478_amb_2024_0005 crossref_primary_10_1007_s10096_021_04360_w crossref_primary_10_1093_jalm_jfab161 crossref_primary_10_7759_cureus_17731 crossref_primary_10_1080_21645515_2023_2266931 crossref_primary_10_1111_imm_13495 crossref_primary_10_2478_rir_2022_0002 crossref_primary_10_31083_j_ceog5012278 crossref_primary_10_3389_fimmu_2023_1156758 crossref_primary_10_1111_dth_15246 crossref_primary_10_1186_s13584_021_00496_4 crossref_primary_10_7717_peerj_18856 crossref_primary_10_1016_j_virs_2023_06_011 crossref_primary_10_1038_s41598_023_50263_5 crossref_primary_10_3389_fimmu_2022_773652 crossref_primary_10_1002_jmv_70161 crossref_primary_10_1186_s41182_022_00468_7 crossref_primary_10_3233_HAB_230004 crossref_primary_10_1007_s00395_021_00883_7 crossref_primary_10_1002_jmv_27385 crossref_primary_10_1016_j_vaccine_2022_01_007 crossref_primary_10_1016_j_jiph_2024_02_016 crossref_primary_10_1080_13102818_2023_2250006 crossref_primary_10_3390_vaccines9080876 crossref_primary_10_1007_s00253_022_12113_8 crossref_primary_10_3390_vaccines10040531 crossref_primary_10_3390_pathogens11020171 crossref_primary_10_3389_fimmu_2022_1095129 crossref_primary_10_1057_s41599_021_00830_w crossref_primary_10_1186_s12916_021_02228_6 crossref_primary_10_1371_journal_pone_0251159 crossref_primary_10_1371_journal_pone_0288557 crossref_primary_10_3389_fimmu_2022_1052424 crossref_primary_10_3389_fimmu_2021_760288 crossref_primary_10_1002_adsr_202400188 crossref_primary_10_1186_s13073_022_01066_2 crossref_primary_10_3390_pharmaceutics14051066 crossref_primary_10_1128_spectrum_02507_21 crossref_primary_10_1038_s41598_022_12750_z crossref_primary_10_1111_apm_13215 crossref_primary_10_3389_fpsyg_2022_1026712 crossref_primary_10_3389_fhumd_2025_1604469 crossref_primary_10_1016_j_jacig_2023_100083 crossref_primary_10_3390_v14051082 crossref_primary_10_1007_s11095_022_03323_w crossref_primary_10_1007_s00705_021_05295_5 crossref_primary_10_1038_s41467_021_24230_5 crossref_primary_10_1002_jmv_27201 crossref_primary_10_1002_jmv_27166 crossref_primary_10_3390_microorganisms11081985 crossref_primary_10_1038_s41598_021_00844_z crossref_primary_10_1038_s41375_021_01288_0 crossref_primary_10_1093_cid_ciab607 crossref_primary_10_1186_s12879_021_06921_y crossref_primary_10_1016_j_jaci_2022_01_005 crossref_primary_10_3389_fimmu_2021_708523 crossref_primary_10_1371_journal_pone_0293652 crossref_primary_10_1111_joim_13304 crossref_primary_10_1093_ofid_ofad598 crossref_primary_10_1038_s41598_025_90324_5 crossref_primary_10_1212_NXI_0000000000001143 crossref_primary_10_1128_msphere_00465_22 crossref_primary_10_3389_fimmu_2021_722027 crossref_primary_10_1128_mSphere_00450_21 crossref_primary_10_3389_fimmu_2022_898520 crossref_primary_10_1007_s12275_022_2037_8 crossref_primary_10_1111_imr_13115 crossref_primary_10_1146_annurev_immunol_101320_125133 crossref_primary_10_3390_jcm11154428 crossref_primary_10_3390_v14040670 crossref_primary_10_1038_s41564_021_00974_0 crossref_primary_10_1007_s10238_023_01276_x crossref_primary_10_2196_38113 crossref_primary_10_3390_v16050672 crossref_primary_10_3390_ijerph19010407 crossref_primary_10_1080_19932820_2024_2348233 crossref_primary_10_1089_vim_2021_0121 crossref_primary_10_3389_fpsyg_2021_810378 crossref_primary_10_3390_diagnostics11101808 crossref_primary_10_1007_s00134_022_06662_9 crossref_primary_10_1007_s11886_022_01786_2 crossref_primary_10_1097_NNR_0000000000000565 crossref_primary_10_3389_fimmu_2022_884879 crossref_primary_10_3390_bios12080621 crossref_primary_10_1038_s41467_021_24979_9 crossref_primary_10_3390_jcm12175460 crossref_primary_10_3389_fimmu_2022_943563 crossref_primary_10_1016_j_labinv_2024_102180 crossref_primary_10_3389_fimmu_2025_1629473 crossref_primary_10_1002_jmv_70335 crossref_primary_10_1016_j_trac_2022_116814 crossref_primary_10_1002_smll_202203309 crossref_primary_10_3390_vaccines9111317 crossref_primary_10_1038_s41423_023_01095_w crossref_primary_10_1371_journal_pone_0281689 crossref_primary_10_1002_acr2_11386 crossref_primary_10_1186_s12979_024_00488_3 crossref_primary_10_1111_jebm_12498 crossref_primary_10_3389_fimmu_2022_1075423 crossref_primary_10_3389_fmicb_2021_789374 crossref_primary_10_2217_fvl_2023_0089 crossref_primary_10_3389_fmed_2022_906469 crossref_primary_10_1007_s11357_022_00546_y crossref_primary_10_3389_fimmu_2022_966098 crossref_primary_10_3389_fimmu_2022_919762 crossref_primary_10_1016_j_mucimm_2023_11_007 crossref_primary_10_1016_j_jcv_2023_105448 crossref_primary_10_1177_13524585221134216 crossref_primary_10_1016_j_arcmed_2021_08_005 crossref_primary_10_1371_journal_pone_0320196 crossref_primary_10_3389_fimmu_2021_701501 crossref_primary_10_3389_fimmu_2022_830710 crossref_primary_10_1016_j_gpb_2021_09_006 crossref_primary_10_1371_journal_pone_0318959 crossref_primary_10_1038_s41392_021_00750_w crossref_primary_10_3390_ijms24054398 crossref_primary_10_1136_bmjopen_2021_051157 crossref_primary_10_3390_vaccines10081268 crossref_primary_10_3947_ic_2024_0145 crossref_primary_10_3390_jcm10194606
Cites_doi	10.1126/science.1085952 10.1038/s41591-020-1083-1 10.1001/jamainternmed.2020.4616 10.1093/cid/ciaa344 10.1016/j.ebiom.2020.102763 10.1016/j.cell.2020.06.044 10.1016/j.immuni.2020.04.023 10.1001/jama.2020.4783 10.1038/s41564-020-00813-8 10.1086/422040 10.1038/s41586-020-2538-8 10.1016/j.cell.2020.05.025 10.1038/s41467-020-19943-y 10.1126/science.abc6284 10.1038/s41591-020-0897-1 10.1128/JVI.00110-09 10.1038/s41591-020-0965-6 10.1515/cclm-2020-0443 10.1136/bmj.m1198 10.1016/j.cell.2020.02.052 10.1128/CVI.00432-06 10.1186/s12977-018-0443-0 10.1056/NEJMc070348 10.1016/j.ijid.2020.03.065 10.1073/pnas.2004168117 10.1038/s41467-020-17488-8
ContentType	Journal Article
Copyright	The Author(s) 2021 The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml	– notice: The Author(s) 2021 – notice: The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID	C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7QR 7SN 7SS 7ST 7T5 7T7 7TM 7TO 7X7 7XB 88E 8AO 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA ARAPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU COVID DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M7P P5Z P62 P64 PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS RC3 SOI 7X8 5PM DOA
DOI	10.1038/s41467-021-22034-1
DatabaseName	Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Ecology Abstracts Entomology Abstracts (Full archive) Environment Abstracts Immunology Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Computer Science Collection ProQuest Central Essentials Local Electronic Collection Information Biological Science Collection ProQuest Central Technology collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Coronavirus Research Database ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Biological Science Database Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China Genetics Abstracts Environment Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection Chemoreception Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Central (New) ProQuest Medical Library (Alumni) Advanced Technologies & Aerospace Collection ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Entomology Abstracts ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) AIDS and Cancer Research Abstracts ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Immunology Abstracts Environment Abstracts ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic Publicly Available Content Database CrossRef
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Biology
EISSN	2041-1723
EndPage	9
ExternalDocumentID	oai_doaj_org_article_87b5e3b2d655425da4c2ff45fb7884d0 PMC7985370 33753738 10_1038_s41467_021_22034_1
Genre	Research Support, Non-U.S. Gov't Journal Article
GrantInformation_xml	– fundername: This work is supported by the National Science and Technology Major Project for Infectious Diseases of China (2018ZX10302206, 2018ZX10723203, and 2017ZX10304402-002-005); the Applied Basic and Frontier Technology Research Project of Wuhan(2020020601012233);the Fundamental Research Funds for the Central Universities (2020kfyXGYJ016, 2020kfyXGYJ028, and 2020kfyXGYJ046); the Tongji-Rongcheng Center for Biomedicine, Huazhong University of Science and Technology, the Medical Faculty of the University of Duisburg-Essen, and Stiftung Universitätsmedizin Essen, University Hospital Essen, Germany. M.T. was supported by the Kulturstiftung Essen and the Deutsche Forschungsgemeinschaft (DFG) through grants RTG 1949/2, TR1208/1-1, and TR1208/2-1. – fundername: ;
GroupedDBID	--- 0R~ 39C 3V. 53G 5VS 70F 7X7 88E 8AO 8FE 8FG 8FH 8FI 8FJ AAHBH AAJSJ ABUWG ACGFO ACGFS ACIWK ACMJI ACPRK ACSMW ADBBV ADFRT ADMLS ADRAZ AENEX AEUYN AFKRA AFRAH AHMBA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AMTXH AOIJS ARAPS ASPBG AVWKF AZFZN BBNVY BCNDV BENPR BGLVJ BHPHI BPHCQ BVXVI C6C CCPQU DIK EBLON EBS EE. EMOBN F5P FEDTE FYUFA GROUPED_DOAJ HCIFZ HMCUK HVGLF HYE HZ~ KQ8 LK8 M1P M48 M7P M~E NAO O9- OK1 P2P P62 PIMPY PQQKQ PROAC PSQYO RNS RNT RNTTT RPM SNYQT SV3 TSG UKHRP AASML AAYXX AFFHD CITATION PHGZM PHGZT PJZUB PPXIY PQGLB CGR CUY CVF ECM EIF NPM 7QL 7QP 7QR 7SN 7SS 7ST 7T5 7T7 7TM 7TO 7XB 8FD 8FK AZQEC C1K COVID DWQXO FR3 GNUQQ H94 K9. P64 PKEHL PQEST PQUKI PRINS RC3 SOI 7X8 PUEGO 5PM
ID	FETCH-LOGICAL-c540t-34f1849c70631f40a2015a2f11fd628ce8ca0f0a4bd9626e175a63e692b6b3713
IEDL.DBID	DOA
ISICitedReferencesCount	172
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000634786600002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	2041-1723
IngestDate	Tue Oct 14 18:59:23 EDT 2025 Tue Nov 04 01:56:02 EST 2025 Fri Sep 05 07:44:03 EDT 2025 Tue Oct 07 07:15:39 EDT 2025 Wed Feb 19 02:29:01 EST 2025 Sat Nov 29 06:29:13 EST 2025 Tue Nov 18 22:19:42 EST 2025 Fri Feb 21 02:39:16 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Language	English
License	Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c540t-34f1849c70631f40a2015a2f11fd628ce8ca0f0a4bd9626e175a63e692b6b3713
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ORCID	0000-0002-8312-9832 0000-0002-0013-5365 0000-0003-3659-3541 0000-0002-5385-083X 0000-0001-9502-9903 0000-0002-5227-4236
OpenAccessLink	https://doaj.org/article/87b5e3b2d655425da4c2ff45fb7884d0
PMID	33753738
PQID	2503525497
PQPubID	546298
PageCount	9
ParticipantIDs	doaj_primary_oai_doaj_org_article_87b5e3b2d655425da4c2ff45fb7884d0 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7985370 proquest_miscellaneous_2504348995 proquest_journals_2503525497 pubmed_primary_33753738 crossref_citationtrail_10_1038_s41467_021_22034_1 crossref_primary_10_1038_s41467_021_22034_1 springer_journals_10_1038_s41467_021_22034_1
PublicationCentury	2000
PublicationDate	2021-03-22
PublicationDateYYYYMMDD	2021-03-22
PublicationDate_xml	– month: 03 year: 2021 text: 2021-03-22 day: 22
PublicationDecade	2020
PublicationPlace	London
PublicationPlace_xml	– name: London – name: England
PublicationTitle	Nature communications
PublicationTitleAbbrev	Nat Commun
PublicationTitleAlternate	Nat Commun
PublicationYear	2021
Publisher	Nature Publishing Group UK Nature Publishing Group Nature Portfolio
Publisher_xml	– name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio
References	LiuWEvaluation of nucleocapsid and spike protein-based enzyme-linked immunosorbent assays for detecting antibodies against SARS-CoV-2J. Clin. Microbiol.202058e0046100420322296057269413 PadoanACosmaCSciacovelliLFaggianDPlebaniMAnalytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kineticsClin. Chem. Lab. Med.202058108110881:CAS:528:DC%2BB3cXhtFKjs7%2FP10.1515/cclm-2020-0443 JinYDiagnostic value and dynamic variance of serum antibody in coronavirus disease 2019Int J. Infect. Dis.20209449521:CAS:528:DC%2BB3cXnsVajtLk%3D10.1016/j.ijid.2020.03.065 WHO. Coronavirus Disease (COVID-19) Situation Dashboard (WHO, accessed 18 Jan 2021). https://covid19.who.int. LongQXAntibody responses to SARS-CoV-2 in patients with COVID-19Nat. Med.2020268458481:CAS:528:DC%2BB3cXot1aktLk%3D10.1038/s41591-020-0897-1 ZhaoJAntibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019Clin. Infect. Dis.202071202720341:CAS:528:DC%2BB3cXisVWhtLvK10.1093/cid/ciaa344 KreerCLongitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patientsCell20201828438541:CAS:528:DC%2BB3cXhsVSlsrzL10.1016/j.cell.2020.06.044 CaoWCLiuWZhangPHZhangFRichardusJHDisappearance of antibodies to SARS-associated coronavirus after recoveryN. Engl. J. Med2007357116211631:CAS:528:DC%2BD2sXhtVGqu7nN10.1056/NEJMc070348 JiangHWSARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responsesNat. Commun.2020112020NatCo..11.3581J1:CAS:528:DC%2BB3cXhsVSmtrrI10.1038/s41467-020-17488-8 National Health Commission of the People’s Republic of China. Guidelines of the Diagnosis and Treatment of New Coronavirus Pneumonia (version 8th) (National Health Commission of the People’s Republic of China, 2020). http://www.nhc.gov.cn/yzygj/s7653p/202008/202000a202007bdf202012bd202004b202046e202005bd202028ca202007f202009a202007f202005e202005a.shtml. SimekMDHuman immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithmJ. Virol.200983733773481:CAS:528:DC%2BD1MXosFKlurg%3D10.1128/JVI.00110-09 JordanREAdabPChengKKCovid-19: risk factors for severe disease and deathBMJ2020368m119810.1136/bmj.m1198 ZhaoJComparison of immunoglobulin G responses to the spike and nucleocapsid proteins of severe acute respiratory syndrome (SARS) coronavirus in patients with SARSClin. Vaccin. Immunol.2007148398461:CAS:528:DC%2BD2sXotlGmu74%3D10.1128/CVI.00432-06 LandaisEMoorePLDevelopment of broadly neutralizing antibodies in HIV-1 infected elite neutralizersRetrovirology20181510.1186/s12977-018-0443-0 EdridgeAWDSeasonal coronavirus protective immunity is short-lastingNat. Med.2020261691169310.1038/s41591-020-1083-1 LiKDynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19Nat. Commun.2020111:CAS:528:DC%2BB3cXisFWlurzF10.1038/s41467-020-19943-y ArvinAMA perspective on potential antibody-dependent enhancement of SARS-CoV-2Nature20205843533631:CAS:528:DC%2BB3cXhsF2ntL3F10.1038/s41586-020-2538-8 NiLDetection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individualsImmunity202052971977 e9731:CAS:528:DC%2BB3cXptlCjtb4%3D10.1016/j.immuni.2020.04.023 HoffmannMSARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitorCell20201812712801:CAS:528:DC%2BB3cXktl2qtb8%3D10.1016/j.cell.2020.02.052 ShenCTreatment of 5 critically ill patients with COVID-19 with convalescent plasmaJAMA2020323158215891:CAS:528:DC%2BB3cXovVSqsr4%3D10.1001/jama.2020.4783 DuanKEffectiveness of convalescent plasma therapy in severe COVID-19 patientsProc. Natl Acad. Sci. USA2020117949094961:CAS:528:DC%2BB3cXnvFeqt78%3D10.1073/pnas.2004168117 LongQXClinical and immunological assessment of asymptomatic SARS-CoV-2 infectionsNat. Med202026120012041:CAS:528:DC%2BB3cXhtF2qtbrM10.1038/s41591-020-0965-6 CaoYPotent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cellsCell202018273841:CAS:528:DC%2BB3cXhtVyiu7fP10.1016/j.cell.2020.05.025 YuJDNA vaccine protection against SARS-CoV-2 in rhesus macaquesScience20203698068112020Sci...369..806Y1:CAS:528:DC%2BB3cXhsF2qsrrN10.1126/science.abc6284 Wu, F. et al. Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China. JAMA Intern Med 180, 1356–1362 (2020). LeungDTAntibody response of patients with severe acute respiratory syndrome (SARS) targets the viral nucleocapsidJ. Infect. Dis.20041903793861:CAS:528:DC%2BD2cXmsFaqtbw%3D10.1086/422040 RotaPACharacterization of a novel coronavirus associated with severe acute respiratory syndromeScience2003300139413992003Sci...300.1394R1:CAS:528:DC%2BD3sXktFGkt7Y%3D10.1126/science.1085952 LiuJLongitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patientsEBioMedicine20205510276310.1016/j.ebiom.2020.102763 Seow J, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 5, 1598–1607 (2020). 22034_CR28 QX Long (22034_CR6) 2020; 26 W Liu (22034_CR5) 2020; 58 Y Jin (22034_CR4) 2020; 94 M Hoffmann (22034_CR8) 2020; 181 J Liu (22034_CR17) 2020; 55 AM Arvin (22034_CR11) 2020; 584 RE Jordan (22034_CR18) 2020; 368 J Yu (22034_CR20) 2020; 369 J Zhao (22034_CR10) 2007; 14 K Duan (22034_CR21) 2020; 117 J Zhao (22034_CR23) 2020; 71 PA Rota (22034_CR7) 2003; 300 K Li (22034_CR2) 2020; 11 E Landais (22034_CR25) 2018; 15 C Shen (22034_CR14) 2020; 323 WC Cao (22034_CR26) 2007; 357 22034_CR13 22034_CR1 C Kreer (22034_CR16) 2020; 182 A Padoan (22034_CR29) 2020; 58 Y Cao (22034_CR19) 2020; 182 AWD Edridge (22034_CR27) 2020; 26 HW Jiang (22034_CR15) 2020; 11 QX Long (22034_CR3) 2020; 26 DT Leung (22034_CR9) 2004; 190 L Ni (22034_CR12) 2020; 52 22034_CR22 MD Simek (22034_CR24) 2009; 83
References_xml	– reference: LiKDynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19Nat. Commun.2020111:CAS:528:DC%2BB3cXisFWlurzF10.1038/s41467-020-19943-y – reference: LandaisEMoorePLDevelopment of broadly neutralizing antibodies in HIV-1 infected elite neutralizersRetrovirology20181510.1186/s12977-018-0443-0 – reference: LiuWEvaluation of nucleocapsid and spike protein-based enzyme-linked immunosorbent assays for detecting antibodies against SARS-CoV-2J. Clin. Microbiol.202058e0046100420322296057269413 – reference: JiangHWSARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responsesNat. Commun.2020112020NatCo..11.3581J1:CAS:528:DC%2BB3cXhsVSmtrrI10.1038/s41467-020-17488-8 – reference: Seow J, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 5, 1598–1607 (2020). – reference: DuanKEffectiveness of convalescent plasma therapy in severe COVID-19 patientsProc. Natl Acad. Sci. USA2020117949094961:CAS:528:DC%2BB3cXnvFeqt78%3D10.1073/pnas.2004168117 – reference: Wu, F. et al. Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China. JAMA Intern Med 180, 1356–1362 (2020). – reference: SimekMDHuman immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithmJ. Virol.200983733773481:CAS:528:DC%2BD1MXosFKlurg%3D10.1128/JVI.00110-09 – reference: LongQXClinical and immunological assessment of asymptomatic SARS-CoV-2 infectionsNat. Med202026120012041:CAS:528:DC%2BB3cXhtF2qtbrM10.1038/s41591-020-0965-6 – reference: HoffmannMSARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitorCell20201812712801:CAS:528:DC%2BB3cXktl2qtb8%3D10.1016/j.cell.2020.02.052 – reference: RotaPACharacterization of a novel coronavirus associated with severe acute respiratory syndromeScience2003300139413992003Sci...300.1394R1:CAS:528:DC%2BD3sXktFGkt7Y%3D10.1126/science.1085952 – reference: ArvinAMA perspective on potential antibody-dependent enhancement of SARS-CoV-2Nature20205843533631:CAS:528:DC%2BB3cXhsF2ntL3F10.1038/s41586-020-2538-8 – reference: KreerCLongitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patientsCell20201828438541:CAS:528:DC%2BB3cXhsVSlsrzL10.1016/j.cell.2020.06.044 – reference: JinYDiagnostic value and dynamic variance of serum antibody in coronavirus disease 2019Int J. Infect. Dis.20209449521:CAS:528:DC%2BB3cXnsVajtLk%3D10.1016/j.ijid.2020.03.065 – reference: LongQXAntibody responses to SARS-CoV-2 in patients with COVID-19Nat. Med.2020268458481:CAS:528:DC%2BB3cXot1aktLk%3D10.1038/s41591-020-0897-1 – reference: CaoWCLiuWZhangPHZhangFRichardusJHDisappearance of antibodies to SARS-associated coronavirus after recoveryN. Engl. J. Med2007357116211631:CAS:528:DC%2BD2sXhtVGqu7nN10.1056/NEJMc070348 – reference: National Health Commission of the People’s Republic of China. Guidelines of the Diagnosis and Treatment of New Coronavirus Pneumonia (version 8th) (National Health Commission of the People’s Republic of China, 2020). http://www.nhc.gov.cn/yzygj/s7653p/202008/202000a202007bdf202012bd202004b202046e202005bd202028ca202007f202009a202007f202005e202005a.shtml. – reference: ShenCTreatment of 5 critically ill patients with COVID-19 with convalescent plasmaJAMA2020323158215891:CAS:528:DC%2BB3cXovVSqsr4%3D10.1001/jama.2020.4783 – reference: EdridgeAWDSeasonal coronavirus protective immunity is short-lastingNat. Med.2020261691169310.1038/s41591-020-1083-1 – reference: PadoanACosmaCSciacovelliLFaggianDPlebaniMAnalytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kineticsClin. Chem. Lab. Med.202058108110881:CAS:528:DC%2BB3cXhtFKjs7%2FP10.1515/cclm-2020-0443 – reference: YuJDNA vaccine protection against SARS-CoV-2 in rhesus macaquesScience20203698068112020Sci...369..806Y1:CAS:528:DC%2BB3cXhsF2qsrrN10.1126/science.abc6284 – reference: CaoYPotent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cellsCell202018273841:CAS:528:DC%2BB3cXhtVyiu7fP10.1016/j.cell.2020.05.025 – reference: NiLDetection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individualsImmunity202052971977 e9731:CAS:528:DC%2BB3cXptlCjtb4%3D10.1016/j.immuni.2020.04.023 – reference: WHO. Coronavirus Disease (COVID-19) Situation Dashboard (WHO, accessed 18 Jan 2021). https://covid19.who.int. – reference: LiuJLongitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patientsEBioMedicine20205510276310.1016/j.ebiom.2020.102763 – reference: LeungDTAntibody response of patients with severe acute respiratory syndrome (SARS) targets the viral nucleocapsidJ. Infect. Dis.20041903793861:CAS:528:DC%2BD2cXmsFaqtbw%3D10.1086/422040 – reference: JordanREAdabPChengKKCovid-19: risk factors for severe disease and deathBMJ2020368m119810.1136/bmj.m1198 – reference: ZhaoJComparison of immunoglobulin G responses to the spike and nucleocapsid proteins of severe acute respiratory syndrome (SARS) coronavirus in patients with SARSClin. Vaccin. Immunol.2007148398461:CAS:528:DC%2BD2sXotlGmu74%3D10.1128/CVI.00432-06 – reference: ZhaoJAntibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019Clin. Infect. Dis.202071202720341:CAS:528:DC%2BB3cXisVWhtLvK10.1093/cid/ciaa344 – ident: 22034_CR28 – volume: 300 start-page: 1394 year: 2003 ident: 22034_CR7 publication-title: Science doi: 10.1126/science.1085952 – volume: 26 start-page: 1691 year: 2020 ident: 22034_CR27 publication-title: Nat. Med. doi: 10.1038/s41591-020-1083-1 – ident: 22034_CR13 doi: 10.1001/jamainternmed.2020.4616 – volume: 71 start-page: 2027 year: 2020 ident: 22034_CR23 publication-title: Clin. Infect. Dis. doi: 10.1093/cid/ciaa344 – volume: 55 start-page: 102763 year: 2020 ident: 22034_CR17 publication-title: EBioMedicine doi: 10.1016/j.ebiom.2020.102763 – volume: 182 start-page: 843 year: 2020 ident: 22034_CR16 publication-title: Cell doi: 10.1016/j.cell.2020.06.044 – volume: 52 start-page: 971 year: 2020 ident: 22034_CR12 publication-title: Immunity doi: 10.1016/j.immuni.2020.04.023 – volume: 323 start-page: 1582 year: 2020 ident: 22034_CR14 publication-title: JAMA doi: 10.1001/jama.2020.4783 – ident: 22034_CR22 doi: 10.1038/s41564-020-00813-8 – volume: 190 start-page: 379 year: 2004 ident: 22034_CR9 publication-title: J. Infect. Dis. doi: 10.1086/422040 – volume: 584 start-page: 353 year: 2020 ident: 22034_CR11 publication-title: Nature doi: 10.1038/s41586-020-2538-8 – volume: 182 start-page: 73 year: 2020 ident: 22034_CR19 publication-title: Cell doi: 10.1016/j.cell.2020.05.025 – ident: 22034_CR1 – volume: 11 year: 2020 ident: 22034_CR2 publication-title: Nat. Commun. doi: 10.1038/s41467-020-19943-y – volume: 369 start-page: 806 year: 2020 ident: 22034_CR20 publication-title: Science doi: 10.1126/science.abc6284 – volume: 26 start-page: 845 year: 2020 ident: 22034_CR3 publication-title: Nat. Med. doi: 10.1038/s41591-020-0897-1 – volume: 83 start-page: 7337 year: 2009 ident: 22034_CR24 publication-title: J. Virol. doi: 10.1128/JVI.00110-09 – volume: 26 start-page: 1200 year: 2020 ident: 22034_CR6 publication-title: Nat. Med doi: 10.1038/s41591-020-0965-6 – volume: 58 start-page: 1081 year: 2020 ident: 22034_CR29 publication-title: Clin. Chem. Lab. Med. doi: 10.1515/cclm-2020-0443 – volume: 368 start-page: m1198 year: 2020 ident: 22034_CR18 publication-title: BMJ doi: 10.1136/bmj.m1198 – volume: 181 start-page: 271 year: 2020 ident: 22034_CR8 publication-title: Cell doi: 10.1016/j.cell.2020.02.052 – volume: 14 start-page: 839 year: 2007 ident: 22034_CR10 publication-title: Clin. Vaccin. Immunol. doi: 10.1128/CVI.00432-06 – volume: 15 year: 2018 ident: 22034_CR25 publication-title: Retrovirology doi: 10.1186/s12977-018-0443-0 – volume: 357 start-page: 1162 year: 2007 ident: 22034_CR26 publication-title: N. Engl. J. Med doi: 10.1056/NEJMc070348 – volume: 94 start-page: 49 year: 2020 ident: 22034_CR4 publication-title: Int J. Infect. Dis. doi: 10.1016/j.ijid.2020.03.065 – volume: 117 start-page: 9490 year: 2020 ident: 22034_CR21 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.2004168117 – volume: 58 start-page: e00461 year: 2020 ident: 22034_CR5 publication-title: J. Clin. Microbiol. – volume: 11 year: 2020 ident: 22034_CR15 publication-title: Nat. Commun. doi: 10.1038/s41467-020-17488-8
SSID	ssj0000391844
Score	2.6679516
Snippet	Long-term antibody responses and neutralizing activities in response to SARS-CoV-2 infection are not yet clear. Here we quantify immunoglobulin M (IgM) and G... A better understanding of longitudinal changes in antibody responses in COVID-19 patients is needed. Here the authors analyze anti-spike and anti-nucleocapsid...
SourceID	doaj pubmedcentral proquest pubmed crossref springer
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	1813
SubjectTerms	13/1 631/250/2152/2153/1291 631/326/596/4130 692/699/255/2514 Adult Aged Antibodies Antibodies, Neutralizing - immunology Antibodies, Viral - immunology Binding Contraction Coronaviruses COVID-19 COVID-19 - immunology Female Humanities and Social Sciences Humans Humoral immunity Immune response Immune response (humoral) Immunity Immunity, Humoral - immunology Immunoglobulin G Immunoglobulin G - immunology Immunoglobulin M Immunoglobulin M - immunology Male Middle Aged multidisciplinary Neutralizing Nucleocapsids SARS-CoV-2 - immunology Science Science (multidisciplinary) Severe acute respiratory syndrome coronavirus 2 Severity of Illness Index Spike Glycoprotein, Coronavirus Spikes Viral diseases
SummonAdditionalLinks	– databaseName: Biological Science Database dbid: M7P link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELaggMSFd2mgICNxA6uJ7aztEyoLFUioVBSq3iLHD7oSTbabXar-e8aOk2p59MItShzJ9szY33jG3yD0kgsRaKFqwqjyhFPjibLMEsmd8VIWsOtHyvxPYn9fHh-rg3Tg1qW0ymFNjAu1bU04I9-BrTowd3Il3szPSKgaFaKrqYTGdXQjsCTQmLp3MJ6xBPZzyXm6K5MzudPxuDKEvARKc8ZJsbYfRdr-v2HNP1Mmf4ubxu1o7-7_DuQeupOAKN7tNec-uuaaB-hWX5ry4iE6P9z9ckim7RGheEjYauDJgip0uOuvXTmLT1an4Y4_noV7Jg4v-pRbaDJrcMho14kvCicC1w570Lz2HAaFu4vT-bKNnLF4-vno4ztSqEfo2977r9MPJBVpIAbA3pIw7mGOlRGAdQrPcw2IotTUF4W3EyqNk0bnPte8tgqcJwdwRU-YmyhaT2oGLvIm2mjaxm0h7IT2qgiRV_DhjPe19sxwp8tayRqAZoaKQVSVSQzmoZDGjypG0pmsevFWIN4qircqMvRq_Gfe83dc2fpt0ICxZeDeji_axfcqmXIlRV06VlM7AShGS6u5od7z0tdCSm7zDG0Pgq_SgtBVl1LP0IvxM5hyiM_oxrWr2IYzDg5wmaHHvbqNPWEM_ErBZIbEmiKudXX9SzM7iXThQgEkE9Ct14PKXnbr31Px5OpRPEW3abCinIEhbaON5WLlnqGb5udy1i2eRzP8BfVFOTY priority: 102 providerName: ProQuest
Title	SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19
URI	https://link.springer.com/article/10.1038/s41467-021-22034-1 https://www.ncbi.nlm.nih.gov/pubmed/33753738 https://www.proquest.com/docview/2503525497 https://www.proquest.com/docview/2504348995 https://pubmed.ncbi.nlm.nih.gov/PMC7985370 https://doaj.org/article/87b5e3b2d655425da4c2ff45fb7884d0
Volume	12
WOSCitedRecordID	wos000634786600002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: DOA dateStart: 20150101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: M~E dateStart: 20100101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Advanced Technologies & Aerospace Database customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: P5Z dateStart: 20100101 isFulltext: true titleUrlDefault: https://search.proquest.com/hightechjournals providerName: ProQuest – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: M7P dateStart: 20100101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: 7X7 dateStart: 20100101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: BENPR dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: PIMPY dateStart: 20100101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bb9MwFLZggMQL4k5gVEbiDawlthPbj1vZxCQo0QZT4cVyHFurxJKpaZn27zl20rJyfeElimpXOjqX-Pvk488IveRCBFmoijCqPOHUeqJqVhPJnfVSZrDqR8n8d2IykdOpKq9c9RV6wnp54N5xO1JUuWMVrQtY-GheG26p9zz3FZA3Xke2ngp1hUzFbzBTQF34cEomZXKn4_GbEDoSKE0ZJ9nGShQF-3-HMn9tlvxpxzQuRAd30Z0BQeLd3vJ76Jpr7qNb_Z2Slw_QxfHu0TEZtyeE4lWnVQNvNcSww11_XsrV-HR5Fg7n41k4IOLwvO-VhSmzBodWdDMIPeFBebXDHlKmvQCbcHd5dr5oo9grHn84OXxDMvUQfTrY_zh-S4bbFYgFlLYgjHtwkbICQErmeWoACuSG-izzdUGlddKa1KeGV7UC1uMAZ5iCuULRqqgYcNtHaKtpG_cEYSeMV1nYMgXyZb2vjGeWO5NXSlaAEBOUrTyt7SA9Hm7A-KrjFjiTuo-OhujoGB2dJejV-j_nvfDGX2fvhQCuZwbR7PgDpJIeUkn_K5UStL0Kvx4qudMAEYNiLFciQS_Ww1CDYWPFNK5dxjmccWCueYIe99mytoQxIISCyQSJjTzaMHVzpJmdRp1voQBLCTDr9Srjfpj1Z1c8_R-ueIZu01AqKYNq2UZbi_nSPUc37bfFrJuP0HUxFfEpR-jG3v6kPBrF-huF1tkSnmX-BUbKw_fl5-8jCTJg
linkProvider	Directory of Open Access Journals
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFD4aHQheuF8CA4wET2Atsd3aeUBodEyr1pWKXTSeQuLYrBJLStNS9U_xGznOpVO57G0PvEWJE9nOd2728XcAXgopHS1UQjkLLRVMWxqmPKVKGG2VCtDql5T5fTkYqJOTcLgGP5uzMC6tstGJpaJOc-3WyDfRVDvmThHKd-Pv1FWNcrurTQmNChZ7ZjHHkK1429vG__uKsZ0Ph91dWlcVoBq9kynlwmJUE2qJxjmwwo_RBLZjZoPAph2mtFE69q0fiyQN0ds3aF_jDjedkCWdhGNMh9-9AuvCgb0F68Pe_vDzclXH8a0rIerTOT5Xm4UodZHLhGDM54IGKxawLBTwN-_2zyTN33ZqSwO4c-t_m7rbcLN2tclWJRt3YM1kd-FaVXxzcQ_mB1ufDmg3P6aMNClpGV6lCPaCFNXBMpOS09mZYzEgI3eSxpBJlVSMTUYZcTn7cc2IRWqK2oJYlK18jpNIisXZeJqXrLik-_G4t02D8D4cXcqoH0AryzPzCIiRsQ0Dt7eMUaq2Nokt18LE7SRUCbrSHgQNNCJdc7S7UiHfojJXgKuoglOEcIpKOEWBB6-X74wrhpILW793iFu2dOzi5Y188jWqlVWkZNI2PGFpB51N1k5joZm1om0TqZRIfQ82GqBFtcoronOUefBi-RiVlduBijOTz8o2ggsM8dsePKzgvewJ5xg5S648kCvAX-nq6pNsdFoSossQnU6J3XrTiMh5t_49FY8vHsVzuL57uN-P-r3B3hO4wZwE-xyFeANa08nMPIWr-sd0VEye1UqAwJfLFp5fZMGVYg
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLbGuIgX7pfAACPBE1hNbKd2HhAaLRXVplIxmCZeguPYrBJLStNS9a_x6zh2kk7lsrc98FY1buU45zuX-PN3EHrGhXCyUBlhNLGEU21JkrOcSG60lTKCqO8l8_fFaCSPjpLxFvrZnoVxtMrWJ3pHnZfavSPvQKh2yp08ER3b0CLG_cHr6XfiOki5nda2nUZtIntmtYTyrXo17MOzfk7p4O3H3jvSdBggGjKVOWHcQoWTaAGBOrI8VBAOY0VtFNm8S6U2UqvQhopneQKZv4FYq7rMdBOadTMG9R387wV0UUCN6eiE4_jz-v2OU16XnDfndEImOxX3XslxIigNGSfRRiz0LQP-luf-Sdf8bc_Wh8LB9f95EW-ga00CjndrxNxEW6a4hS7XLTlXt9HyYPfDAemVh4TilqhWwKccIFDhqj5uZnJ8vDhx2gZ44s7XGDyrqcYwZFJgx-RXjU4WboRrK2wBceUSFhRXq5PpvPRaubj3_nDYJ1FyB306l7u-i7aLsjD3ETZC2SRyO85Qu2prM2WZ5kbFWSIzSLADFLVmkupGud01EPmWegYBk2ltWimYVupNK40C9GL9m2mtW3Lm6DfO-tYjnea4_6KcfU0bF5ZKkcWGZTTvQgpK41xxTa3lsc2ElDwPA7TTGl3aOMIqPbW4AD1dXwYX5valVGHKhR_DGYfCPw7QvdrU1zNhDOppwWSAxAYINqa6eaWYHHuZdJFAKipgWi9buJxO699L8eDsu3iCrgBi0v3haO8hukodmEMGeN5B2_PZwjxCl_SP-aSaPfbeAKMv542cX7m3nMU
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=SARS-CoV-2+infection+induces+sustained+humoral+immune+responses+in+convalescent+patients+following+symptomatic+COVID-19&rft.jtitle=Nature+communications&rft.au=Wu%2C+Jun&rft.au=Liang%2C+Boyun&rft.au=Chen%2C+Cunrong&rft.au=Wang%2C+Hua&rft.date=2021-03-22&rft.pub=Nature+Publishing+Group+UK&rft.eissn=2041-1723&rft.volume=12&rft.issue=1&rft_id=info:doi/10.1038%2Fs41467-021-22034-1&rft.externalDocID=10_1038_s41467_021_22034_1
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2041-1723&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2041-1723&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2041-1723&client=summon